Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
eVOLVE-Lung02: Volrustomig plus chemotherapy vs pembrolizumab plus chemotherapy in metastatic NSCLC with PD-L1 < 50%
jRCT2031230678Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Oct 2023
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised trial of volrustomig in non-small cell lung cancer (NSCLC) (2 arms), sponsored by AstraZeneca. Primary endpoints: Progression-Free Survival in PD-L1-negative participants and Overall Survival in PD-L1-negative participants. Started Oct 2023; status: active, not recruiting.
02
Drugs
volrustomig
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2031230678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230678.